---
document_datetime: 2026-01-27 12:53:13
document_pages: 8
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/rybelsus-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: rybelsus-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.730738
conversion_datetime: 2026-01-29 11:59:10.403316
docling_version:
  docling-serve: 1.11.0
  docling-jobkit: 1.9.0
  docling: 2.70.0
  docling-core: 2.61.0
  docling-ibm-models: 3.11.0
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Rybelsus

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                   | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type II /  | This was an application for a variation | 27/11/2025                          |                                             | SmPC and PL                      |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000292593                     | following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.3 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet of human medicinal products intended to implement the outcome of a procedure concerning PSUR or PASS, or the outcome of the assessment done by the competent authority under Articles 45 or 46 of Regulation 1901/2006 - C.I.3.z Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet of veterinary medicinal products intended to implement the outcome of a procedure concerning PSUR: implementation of wording agreed by the competent authority - Accepted Update of section 4.8 of the SmPC in order to add Dysaesthesia to the list of adverse drug reactions (ADRs) for Ozempic and Rybelsus following PRAC request for cumulative review of 'Altered skin sensation' for semaglutide PSUR (EMEA/H/C/PSUSA/00010671/202405); the   |            |     |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IB / EMA/VR/0000294825 | B.I.e.5 Implementation of changes foreseen in an approved change management protocol - B.I.e.5.c Implementation of a change for a biological/immunological                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 17/11/2025 | N/A |

<div style=\"page-break-after: always\"></div>

|                                       | medicinal product - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |             |
|---------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-------------|
| Variation type II / EMA/VR/0000249026 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Update of sections 4.4 and 4.8 of the SmPC in order to add a new warning on gastroparesis following review of the data from clinical trials; the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to bring editorial | 23/10/2025 | SmPC and PL |
| Variation type IB / EMA/VR/0000287437 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. - - Accepted C.I.z - to update sections 4.4 and 4.8 of the SmPC and sections 2 and 4 of the Package                                                                                                                                                                                                                                                                                                                                                                        | 25/09/2025 | SmPC and PL |

<div style=\"page-break-after: always\"></div>

|                                       | Leaflet to include the warning for Non- Arteritic Anterior Ischemic Optic Neuropathy (NAION) in line with the outcome of the Pharmacovigilance Risk Assessment Committee (PRAC) Assessment Report for the Post-Authorisation Measure Procedures EMA/PAM/0000262449, EMA/ PAM/0000262475, and EMA/PAM/0000262468 of PSUR EMEA/H/C/PSUSA/00010671/202405 (1 June 2023 - 31 May 2024).                                                                                                                                                                                                                                                                                                             |            |             |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-------------|
| Variation type II / EMA/VR/0000244874 | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted A grouped application consisting of: C.I.4: Update of sections 4.1, 4.2, 4.4, 4.8, and 5.1 of the SmPC in order to update clinical efficacy and safety information based on the final results from study EX9924- 4473(SOUL); this is a phase 3b study | 18/09/2025 | SmPC and PL |

<div style=\"page-break-after: always\"></div>

|                                       | comparing oral semaglutide versus placeboand added to standard of care in patients with type 2 diabetes at high risk of cardiovascular events; the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce editorial changes to the PI. C.I.4: Update of sections 4.2, and 5.1 of the SmPC in order to introduce chronic kidney disease outcomes based on final results from study NN9535- 4321 (FLOW); this is a phase 3b study evaluating the effect of semaglutide versus placebo on the progression of renal impairment in subjects with type 2 diabetes and chronic kidney disease; the Package Leaflet is updated accordingly.   |            |     |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IB / EMA/VR/0000282011 | This was an application for a group of variations. B.II.d.2 Change in test procedure for the finished product - B.II.d.2.a Minor changes to an approved test procedure - Accepted B.II.d.2 Change in test procedure for the finished product - B.II.d.2.d Other changes to a test procedure (including replacement or addition) - Accepted                                                                                                                                                                                                                                                                                                                                    | 29/08/2025 | N/A |
| Variation type IB / EMA/VR/0000269116 | B.I.c.1 Change in immediate packaging of the active substance - B.I.c.1.a Qualitative                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 03/06/2025 | N/A |

<div style=\"page-break-after: always\"></div>

|                                       | and/or quantitative composition - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |            |     |             |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------|
| Variation type II / EMA/VR/0000249034 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Update of section 4.8 of the SmPC in order to add headache to the list of adverse drug reactions (ADRs) with frequency common following review of the clinical trial and post- marketing data; the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to bring editorial | 22/05/2025 |     | SmPC and PL |
| Variation type IB / EMA/VR/0000263278 | B.II.g.5 Implementation of changes foreseen in an approved change management protocol - B.II.g.5.c Implementation of a change for a biological/immunological medicinal product - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 02/05/2025 | N/A |             |

<div style=\"page-break-after: always\"></div>

| Variation type IB / EMA/VR/0000256146   | B.I.e.4 Changes to an approved change management protocol - B.I.e.4.b Minor changes to an approved change management protocol that do not change the strategy defined in the protocol - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 21/03/2025   | N/A   |
|-----------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|
| Variation type IB / EMA/VR/0000246407   | This was an application for a group of variations. B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.a The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer - Accepted B.I.a.3 Change in batch size (including batch size ranges) of active substance or intermediate used in the manufacturing process of the active substance - B.I.a.3.a Up to 10-fold increase compared to the originally approved batch size - Accepted | 19/02/2025   | N/A   |

<div style=\"page-break-after: always\"></div>

| PSUR / EMA/PSUR/0000296561   | - -   |
|------------------------------|-------|